Race Oncology Limited
RAONF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.00 | -0.60 | 2.31 | -1.02 |
| FCF Yield | -1.43% | -3.17% | -3.05% | -1.08% |
| EV / EBITDA | -68.91 | -20.00 | -27.22 | -49.13 |
| Quality | ||||
| ROIC | 2.30% | -52.99% | -25.59% | -27.10% |
| Gross Margin | 89.49% | 55.52% | 91.03% | 60.27% |
| Cash Conversion Ratio | 0.96 | 0.69 | 1.07 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.47% | 78.17% | 100.75% | 64.37% |
| Free Cash Flow Growth | 52.08% | 10.38% | -70.21% | -33.21% |
| Safety | ||||
| Net Debt / EBITDA | 3.08 | 1.21 | 0.15 | 0.52 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -261.16 | -157.82 | -630.34 | -1,050.11 |